A selective Y1R ligand (Asn6, Pro34-NPY) co-administered with tariquidar (a P-glycoprotein inhibitor) exerted a synergistic effect and improved the therapeutic efficacy against multidrug-resistant breast cancer cells [108]. Here, NPY is linked to breast carcinoma.